viewEyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals wins approval from FDA for eye-inflammation implant

The approved implant Yutiq is a micro-insert that delivers fluocinolone acetonide to the affected portion of the eye over three years

EyePoint is a specialty biopharma company that develops ophthalmic products for patients with eye disorders

The biopharmaceutical company Eye Point Pharmaceuticals (NASDAQ:EYPT) is on the receiving end of good news as the US Food and Drug Administration gave the green light to its drug implant Yutiq, which treats uveitis, a form of eye inflammation, hitting the posterior segment of the eye.

Yutiq is a micro-insert that delivers fluocinolone acetonide to the affected portion of the eye over three years. Yutiq can be administered in the physician’s office.

The FDA’s approval of Yutiq is based on two Phase 3 trials evaluating Yutiq in which patient follow-up continued for three years. After six and 12 months, both clinical trials achieved the primary endpoint of the prevention of recurrent uveitis flares.

READ: EyePoint Pharmaceuticals reports miss on results, but focus shifts to drugs poised for commercial rollout

In controlled clinical trials, the most common adverse reactions reported by patients treated with Yutiq were cataract development and an increase in intraocular pressure.

Uveitis is a form of eye inflammation with limited treatment options and is the third leading cause of blindness in the US.

Headquartered in Watertown, Massachusetts, EyePoint is a specialty biopharmaceutical company that develops ophthalmic products.

Eye Pharmaceuticals shares shot up 2% to $3.30 in Monday’s afternoon trading session after the FDA's approval of Yutiq.

Contact Ellen Kelleher at [email protected]

Quick facts: EyePoint Pharmaceuticals Inc

Price: 0.6064 USD

Market: NASDAQ
Market Cap: $76.32 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Medexus Pharmaceuticals sees record revenue and more strong growth beyond 1Q...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:PDDPF) CEO Ken d’Entremont tells Proactive the specialty pharmaceutical company posted record revenue of C$27.5 million during its fiscal first-quarter thanks to strong sales of its four leading drug products. d’Entremont says he sees because the...

29 minutes ago

2 min read